Your browser doesn't support javascript.
loading
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".
Rand, Kim; Ramos-Goñi, Juan Manuel; Akmaz, Bülent; Solé-Feu, Laia; Armario-Hita, José-Carlos.
Affiliation
  • Rand K; Maths in Health B.V., Schoolstraat 21, 6343CD, Klimmen, The Netherlands. krand@mathsinhealth.com.
  • Ramos-Goñi JM; Maths in Health B.V., Schoolstraat 21, 6343CD, Klimmen, The Netherlands.
  • Akmaz B; Global Market Access, Pricing and Medical Affairs, Barcelona, Spain.
  • Solé-Feu L; Global Market Access, Pricing and Medical Affairs, Barcelona, Spain.
  • Armario-Hita JC; Department of Dermatology, University Hospital of Puerto Real, University of Cadiz, Cádiz, Spain.
Dermatol Ther (Heidelb) ; 14(3): 823-827, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38438784
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Dermatol Ther (Heidelb) Year: 2024 Document type: Article Affiliation country: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Dermatol Ther (Heidelb) Year: 2024 Document type: Article Affiliation country: Netherlands